Wall Street smiles on first US autologous aesthetic cell therapy approval
This article was originally published in Scrip
Executive Summary
Shares of Fibrocell Science soared as high as 54.3%, or 63 cents, on 22 June after the company revealed that the US FDA granted approval to laVív (azficel-T) as a treatment to improve the appearance of moderate-to-severe nasolabial fold wrinkles, or smile lines, in adults. The drug is the first and only autologous aesthetic cell therapy approved for that indication.